
effect growth hormone hypothalamo-pituitary 
dwarfism. i. metabolic effects human growth hormone. 
human growth hormone, isolated raben's 
method, given 2 5 mg. daily 
doses periods 1 12 days 7 patients 
pituitary-hypothalamic dwarfism. 
metabolic effects follows: 
nitrogen retention variable 
reduction blood urea.  plasma amino-acid 
concentration alter 
i.m. injection hormone fasting. 
accompanying retention intracellular 
components, proportions required 
protoplasm formation. 
isotonic expansion extracellular compartment, 
without change plasma 
electrolyte concentrations.  retention phosphorus, 
sometimes rise plasma 
phosphate; increased intestinal calcium absorption, 
hypercalciuria, alteration 
plasma calcium; increase plasma citrate 
citrate urinary excretion; 
calcium phosphate retention reversed 
stopping treatment.  mobilisation 
fat stores lipid catabolism: 
accompanied well marked 
increase nefa concentration hours 
hormone injection 
fasting state, period hypoglycaemia 
low nefa levels.  complex, 
biphasic action glucose metabolism.  fasting 
blood sugar levels altered, 
glycaemia various tests 
fasting, insulin injections, tolbutamide 
administration, intestinal hyperglycaemia. 
acceleration intermediate 
metabolism increased blood citrate 
concentrations 24 hours urinary 
excretion  -ketoglutaric acid.  one test 
fasting blood citrate increased 
4 hours hormone injection.  
oral load sugar blood citrate 
 -ketoglutaric acid concentrations 
alter.  progressive gain 
weight found treatment, partly 
reversible stopping treatment, 
correlating intracellular nitrogen retention 
expansion extracellular 
space, despite mobilisation fat reserves. 
